Katie F. Maass

TL;DR: In the phase 2 Ladder trial, the PDS was generally well tolerated and demonstrated a dose response across multiple end points in patients with nAMD, and has the potential to reduce treatment burden in nAMD while maintaining vision.

TL;DR: In this article, the authors evaluated the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD).

TL;DR: A kinetic model for ADC cellular processing as well as generalizable methods based on flow cytometry and fluorescence imaging to parameterize this model can be incorporated into larger pharmacokinetics/pharmacodynamics models, as demonstrated in the associated companion paper.

TL;DR: A systems pharmacokinetic model for intracellular processing of ADCs has been proposed to highlight the current understanding about the determinants of ADC activation inside a cell.

TL;DR: A model-based meta-analysis was conducted in humans and nonclinical species and mathematical formulae are presented that allow prediction of the ocular t½ for molecules of interest, successfully demonstrated in case studies of aflibercept, brolucizumab, and PEGylated Fabs, where the predicted t½ values are found to be in reasonable agreement with the experimental data available.